AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Files An 8-K Regulation FD Disclosure

AYTU BIOSCIENCE, INC. (OTCMKTS:AYTU) Files An 8-K Regulation FD Disclosure
Item 7.01 Regulation FD Disclosure.

On June 27, 2020, Aytu BioScience, Inc. (the “Company”) and Biolidics, Limited (“Biolidics”) signed a letter of intent to, among other things, document the parties’ mutual intention to enter into a joint development agreement (the “Joint Development Agreement”) in order to advance the development of and, if successful, commercialize a new SARS-CoV-2 diagnostic test (the \”Proposed Collaboration\”). The Company and Biolidics are in the process of negotiating the definitive terms of this Proposed Collaboration. The Company and Biolidics believe a next generation SARS-CoV-2 test may address an important clinical need as the 2019 Novel Coronavirus (“SARS-CoV-2 coronavirus” or “COVID-19”) health crisis continues to unfold and the needs associated with patient testing continue to evolve. Stockholders are reminded that there can be no assurance the Company will enter into a Joint Development Agreement with Biolidics for the Proposed Collaboration or that a new SARS-CoV-2 diagnostic test will be successfully developed. The Company will make the appropriate announcement(s) if and when there are further material developments relating to the Proposed Collaboration.
As previously announced, the Company also has a distribution agreement in place with L.B Resources, Limited (L.B. Resources) and is sourcing an FDA Emergency Use Authorized SARS-CoV-2 IgG/IgM antibody test kits (“Orient Gene Test Kit(s)”) manufactured by Zhejiang Orient Gene Biotech, Limited (“Orient Gene”). The Orient Gene Test Kits received Emergency Use Authorization (“EUA) from the U.S. Food and Drug Administration (“FDA”) on May 29, 2020 following the completion of the FDA’s commissioning of an independent validation, which was conducted by the National Cancer Institute. This independent laboratory evaluation demonstrated high sensitivity and specificity of the test. Virtually all antibody test kits in the Company’s warehouse and those tests that have been sold to date have been sourced from Orient Gene. Through its relationship with L.B. Resources in sourcing the Orient Gene Test Kits, the Company believes it has access to adequate supply of these FDA EUA Orient Gene Test Kits now and expects to have supply as needed in the future.
Accordingly, and in connection with the planned Joint Development Agreement, the Company and Biolidics have mutually agreed to terminate their distribution agreement with effect from June 27, 2020. Each party shall release the other party of all the obligations and duties under the Agreement, and all monies paid by the Company to Biolidics for inventory orders placed but not received will be returned. This termination does not materially affect the Company’s supply of test kits. Also, in connection with the planned Joint Development Agreement, Biolidics has begun the process to voluntarily withdraw its application to the US FDA for EUA to the FDA Serology Test Policy.
Forward-Looking Statement
This current report on Form 8-K includes forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, or the Exchange Act. All statements other than statements of historical facts contained in this presentation, are forward-looking statements. Forward-looking statements are generally written in the future tense and/or are preceded by words such as \’\’may,\’\’ \’\’will,\’\’ \’\’should,\’\’ \’\’forecast,\’\’ \’\’could,\’\’ \’\’expect,\’\’ \’\’suggest,\’\’ \’\’believe,\’\’ \’\’estimate,\’\’ \’\’continue,\’\’ \’\’anticipate,\’\’ \’\’intend,\’\’ \’\’plan,\’\’ or similar words, or the negatives of such terms or other variations on such terms or comparable terminology. These statements are just predictions and are subject to risks and uncertainties that could cause the actual events or results to differ materially. These risks and uncertainties include, among others: (i) whether negotiations between us and Biolidics will be successful and result in the entry into a Joint Development Agreement for the development of a new SARS-CoV-2 diagnostic test, (ii) the ability to successfully develop and commercialize a new SARS-CoV-2 diagnostic test even if we are able to enter into a Joint Development Agreement with Biolidics, market and consumer acceptance of any new SARS-CoV-2 diagnostic test developed if any, if we enter into a Joint Development Agreement with Biolidics, (iii) our ability to obtain FDA clearance for a new SARS-CoV-2 diagnostic test if it is developed, (iv) our ability to successfully market and sell any of our COVID-19 Rapid Test kits, whether supplied by L.B Resources or Biolidics (the “COVID-19 Rapid Test Kits”), as a result of increased scrutiny and media attention around the accuracy of serology tests in the detection of SARS-CoV-2 coronavirus, (v) the adequacy of our supply of COVID-19 Rapid Test Kits to meet future demand, or (vi) our ability to enforce our exclusive U.S. distribution agreement with Orient Gene and our ability to obtain future Orient Gene Test Kits from Orient Gene. We also refer you to the risks described in \’\’Risk Factors\’\’ in Part I, Item 1A of our Annual Report on Form 10-K and in the other reports and documents we file with the Securities and Exchange Commission from time to time.
In accordance with General Instruction B.2 of Form 8-K, the information under this Item 7.01 shall not be deemed to be “filed” for purposes of Section 18 of the Securities Exchange Act of 1934, as amended (the “Exchange Act”), nor shall such information be deemed incorporated by reference in any filing under the Securities Act of 1933, as amended, or the Exchange Act, except as shall be expressly set forth by specific reference in such filing.

Story continues below

Aytu BioScience, Inc. is a commercial-stage healthcare company focused on acquiring, developing and commercializing products in the field of urology. The Company focuses on hypogonadism, prostate cancer, urinary tract infections and male infertility. The Company markets ProstaScint (capromab pendetide), a radio imaging agent indicated to detect the prostate specific membrane antigen (PSMA) in the assessment and staging of prostate cancer. The Company also markets Primsol (trimethoprim hydrochloride), a trimethoprim-only oral solution for urinary tract infections. The Company’s pipeline includes MiOXSYS, an in vitro diagnostic device. MiOXSYS system is a point-of-care semen analysis system, used for diagnosis and management of male infertility. The Company holds the United States rights to Natesto (testosterone), a formulation of testosterone delivered through a nasal gel. Natesto is used for the treatment of hypogonadism (low testosterone) in men.

An ad to help with our costs